Table 1 Characteristics of the all patients, and comparison between plasma group and control group
Variables | Total N = 59 | Plasma group N = 33 | Control group N = 26 | p value |
|---|---|---|---|---|
Age (months) | 18.00 (10.00–36.00) | 18.00 (11.00–38.50) | 16.50 (7.75–32.50) | 0.647 |
Male,n (%) | 40 (67.8) | 23 (69.7) | 17 (65.4) | 0.725 |
Weight(kg) | 10.00 (9.00–13.00) | 10.00 (9.75–13.00) | 10.00 (8.28–12.50) | 0.386 |
Fever daysa | 10.00 (7.00–14.00) | 11.00 (8.00–14.50) | 9.50 (7.00–14.50) | 0.540 |
Co-infection, n (%) | 17 (28.8) | 12 (36.4) | 5 (19.2) | 0.149 |
Blood routine and infection indicators | ||||
 Leukocyte,109/L | 5.60 (2.70–9.70) | 5.60 (2.70–8.85) | 5.85 (2.60–11.50) | 0.867 |
 Hemoglobin,(g/L) | 92.00 ± 17.37 | 88.82 ± 14.79 | 96.04 ± 19.75 | 0.114 |
 Neutrophil, 109/L | 3.74 (1.48–6.85) | 3.74 (1.56–6.84) | 1.36 (1.36–8.76) | 0.963 |
 Platelets, 109/L | 201.00 (117.00–319.00) | 188.00 (125.00–254.50) | 252.00 (100.00–354.75) | 0.296 |
 C reactive protein, mg/L | 36.70 (11.88–58.20) | 42.10 (12.54–70.35) | 27.31 (9.00–54.08) | 0.445 |
Organ function indicators, n (%) | ||||
 Alanine transaminase>50 U/L | 16 (27.1) | 10 (30.3) | 6 (23.1) | 0.535 |
 Serum creatinine >62 umol/L | 1 (1.7) | 1 (3.0) | 0 (0.0) | 1.00 |
 Creatine kinase isoenzyme>37 U/L | 21 (35.6) | 10 (30.3) | 11 (42.3) | 0.339 |
 Prothrombin time>15 s | 11 (18.6) | 5 (15.2) | 6 (23.1) | 0.438 |
 Activated partial prothrombin time>45 s | 28 (47.5) | 17 (51.5) | 11 (42.3) | 0.482 |
 Fibrinogen<2 g/L | 15 (25.4) | 6 (18.2) | 9 (34.6) | 0.150 |
Adenovirus genotype, n (%) | Â | Â | Â | 0.156 |
 ADV3 | 5 (8.5) | 4 (12.1) | 1 (3.8) |  |
 ADV7 | 52 (88.1) | 29 (87.9) | 23 (88.5) |  |
 Unkown | 2 (3.4) | 0 (0.0) | 2 (7.7) |  |
Severity of Illness, n (%) | ||||
 SOFA score ≥ 7 | 33 (55.9) | 15 (42.4) | 18 (69.2) | 0.068 |
 OI ≥ 8 | 35 (59.3) | 21 (63.6) | 14 (53.8) | 0.447 |
Treatment, n (%) | ||||
 Human immunoglobulin | 52 (88.1) | 31 (93.9) | 21 (80.8) | 0.120 |
 Glucocorticoid | 35 (59.3) | 20 (60.6) | 15 (57.7) | 0.821 |
 Vasoactive drug | 36 (61.0) | 20 (60.6) | 16 (61.5) | 0.942 |
Secondary outcomes, (days) | ||||
 Fever days after adenovirus genotype determined | 3.00 (2.00–6.00) | 3.00 (2.00–5.00) | 4.50 (2.00–7.00) | 0.232 |
 Duration of invasive mechanical ventilation | 14.00 (8.00–22.00) | 15.00 (10.00–23.00) | 11.00 (7.00–20.00) | 0.207 |
 Hospital length of stay | 32.00 (21.00–40.00) | 17.00 (12.50–25.00) | 15.50 (8.50–24.25) | 0.249 |
Primary outcome | ||||
 Mortality, n (%) | 17 (28.8) | 6 (18.2) | 11 (42.3) | 0.042 |